+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a combined treatment using KarXT and KarX-EC in adults aged 55 to 90 years who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study is sponsored by Bristol-Myers Squibb and aims to address agitation symptoms in this population by comparing the study drugs against placebo. Participants have a confirmed Alzheimers diagnosis and agitation symptoms as defined by recognized criteria. Participants receive either the combined drugs KarXT and KarX-EC or a placebo, with doses given on specified days. The study is designed with parallel groups and maintains blinding to ensure unbiased results. This treatment period lasts 14 weeks, during which the effects on agitation and related symptoms are closely monitored. During the trial, participants and their caregivers attend regular visits to assess changes in agitation using established tools like the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association CMAI-IPA and other scales. Safety is monitored through adverse event tracking, physical exams, laboratory tests, vital signs, and electrocardiograms. The study also evaluates cognitive and behavioral changes up to 18 weeks, with caregivers playing a key role in reporting participant status and medication adherence.

Age: 55Years - 90YearsAll GendersPhase 3
162 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a drug called brenipatide when added to standard treatment for adults with major depressive disorder. The study compares brenipatide plus standard care to a placebo plus standard care to see if it can delay the return of major depressive symptoms. This is a phase 3, randomized, double-blind trial sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all given by subcutaneous injection along with their standard care. The study has four periods a screening phase lasting about one month, a combined treatment and post-treatment phase lasting at least 12 months, and a safety follow-up period of about two months. The total participation time may vary and can be shortened if symptoms worsen or if participants withdraw. During the study, participants will self-inject the study medication and keep electronic and paper diaries, complete questionnaires, and attend scheduled visits. Researchers will measure the time to relapse of major depressive disorder symptoms as the main outcome. Other assessments include changes in body weight, depression severity, functional impairment, anxiety levels, quality of life, and presence of treatment-related antibodies. Safety monitoring will continue throughout the study and follow-up periods.

Age: 18Years - 75YearsAll GendersPhase 3
170 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of brenipatide, given alongside standard of care, compared with a placebo plus standard of care, in delaying the worsening of symptoms in adults with bipolar disorder. This phase 2, randomized, double-blind study aims to better understand how brenipatide might help manage bipolar disorder symptoms over time. Participants receive either one of two doses of brenipatide or a placebo, both administered by subcutaneous injection, combined with their standard bipolar disorder treatment. The study includes three main periods a screening period lasting about one month, a treatment period lasting at least six months, and a follow-up period of about two months. Study participation may be shortened if symptoms worsen or if the participant chooses to withdraw. During the study, participants are asked to self-inject the study medication, keep electronic and paper diaries, and complete questionnaires. Researchers will monitor outcomes such as time to relapse, changes in disability, depression and mania scores, quality of life, patient impressions, body weight changes, and treatment-related antibody development. Safety and effectiveness measures will be collected throughout treatment and follow-up, with total participation lasting around nine months or less depending on individual circumstances.

Age: 18Years - 75YearsAll GendersPhase 2
87 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of brenipatide alongside standard of care SoC compared to a placebo plus SoC in adult participants with major depressive disorder. This Phase 3 trial aims to delay the return of major depressive symptoms and is sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all administered by subcutaneous injection in addition to their standard treatment. The study includes a screening period lasting about one month, followed by a treatment period and potential post-treatment phase that together last at least 12 months. Throughout the trial, participants will self-inject the study medication and complete electronic and paper diaries along with questionnaires. Researchers will monitor the time to relapse of major depressive disorder and assess changes in depression rating scales, body weight, functional impairment, anxiety, quality of life, and other patient-reported outcomes. The follow-up period after treatment will last approximately 2 months.

Age: 18Years - 75YearsAll GendersPhase 3
180 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of brenipatide combined with standard treatment compared to placebo with standard treatment in adults with schizophrenia. This phase 2 study aims to understand how brenipatide affects body weight and other clinical measures in this population. The trial is sponsored by Eli Lilly and Company and includes adults aged 18 to 55 years diagnosed with schizophrenia. Participants will be randomly assigned to receive either brenipatide or placebo, both administered by subcutaneous injection alongside their usual schizophrenia care. The study is double-blind, meaning neither participants nor researchers will know who receives the active drug or placebo. The trial consists of three periods a screening period of about one month, a treatment period lasting up to 12 months, and a follow-up period of approximately two months. During the study, participants will attend regular visits for assessments including body weight changes, cognitive testing, symptom severity scales, and functional capacity evaluations. Researchers will also monitor safety through laboratory tests and measure drug levels and immune responses. The total participation time may be up to 15 months, including screening, treatment, and follow-up to evaluate outcomes and safety comprehensively.

Age: 18Years - 55YearsAll GendersPhase 2
101 locations
P

Actively Recruiting

Researchers are evaluating the drug brenipatide compared to a placebo to see if it works and is safe for adults with Alcohol Use Disorder AUD and hazardous alcohol use. This phase 3 study aims to understand how brenipatide affects drinking patterns over time. Participation in this trial will last about 56 weeks, with careful monitoring throughout. Participants will receive brenipatide or placebo through subcutaneous injections. The study includes escalating doses of brenipatide administered under the skin. Participants must self-inject the study drug or receive assistance from a trained support person if needed. The treatment phase is structured in parallel groups, comparing the drug against placebo. During the study, participants will attend regular visits and be asked to maintain study diaries and complete questionnaires. Researchers will assess changes in drinking patterns using the Timeline Followback Method, daily alcohol consumption, alcohol cravings, and health outcomes such as body weight and quality of life. Blood samples will be collected to measure brenipatide levels and monitor for any immune responses. The study includes safety monitoring and lasts for approximately 56 weeks.

Age: 18Years - 75YearsAll GendersPhase 3
115 locations
P

Actively Recruiting

Researchers are evaluating brenipatide, a drug given as a subcutaneous injection, compared to a placebo to understand its effects and safety in adults with moderate-to-severe Alcohol Use Disorder AUD. The study is a Phase 3, multicenter, randomized, double-blind trial sponsored by Eli Lilly and Company. The trial aims to assess changes in drinking patterns over a period of up to 56 weeks. Participants receive escalating doses of the study drug or placebo administered by subcutaneous injection. The study includes two experimental periods with LY3537031 and a placebo group. Participants will self-inject the study intervention, keep diaries, and complete questionnaires throughout the trial. The trial design includes random assignment to one of the study groups, and treatment is monitored over the full 56 weeks. During the study, participants will attend regular visits to monitor their alcohol consumption using the Timeline Followback method, assess alcohol cravings with the Penn Alcohol Craving Scale, and evaluate health outcomes including body weight and quality of life measures. Researchers will also study the drugs pharmacokinetics and the presence of anti-drug antibodies. Participation lasts about 56 weeks, with ongoing safety and efficacy assessments throughout this period.

Age: 18Years - 75YearsAll GendersPhase 3
117 locations
R

Actively Recruiting

Researchers are evaluating how well different doses of esketamine nasal spray work compared to a placebo in adults with treatment-resistant depression. This study focuses on individuals with major depressive disorder who have not improved after trying at least two different antidepressant treatments during their current depressive episode. The trial is designed to better understand the efficacy, safety, and tolerability of esketamine when used alone. Participants will be randomly assigned to receive either 56 mg or 84 mg of esketamine nasal spray, or a placebo, twice a week for four weeks in a double-blind phase. Those who finish this phase may join an open-label phase, where they can receive either 56 mg or 84 mg of esketamine for up to 12 weeks. The medication is self-administered as a nasal spray. During the study, participants will have regular evaluations measuring changes in depression symptoms using the Montgomery-Asberg Depression Rating Scale MADRS and other assessment tools. Researchers will monitor symptom changes from baseline through the double-blind and open-label phases. Safety and tolerability will also be tracked throughout the study, which is expected to continue until 2029.

Age: 18Years +All GendersPhase 3
39 locations
L

Actively Recruiting

Researchers are studying the long-term safety and tolerability of KarXT for treating mania or mania with mixed features in adults with Bipolar-I disorder. This phase 3 open-label extension trial focuses on participants who have either completed prior related studies or are newly diagnosed with specific criteria. The study aims to monitor adverse events and changes in symptoms over an extended period. Participants receive KarXT at specified doses, with some possibly receiving additional therapeutic doses of Lithium, Valproate, or Lamotrigine. The study does not involve placebo and is designed as a single-group intervention. The treatment and monitoring continue for up to 54 weeks, focusing on safety and symptom assessments. During the study, participants undergo regular evaluations including psychiatric assessments and safety monitoring. Researchers track treatment-emergent adverse events, serious adverse events, and changes in suicidal ideation using the Columbia-Suicide Severity Rating Scale. Additional assessments include rating scales for movement disorders and urinary symptoms. The total participation period extends up to about one year, with ongoing safety and tolerability evaluations.

Age: 18Years - 65YearsAll GendersPhase 3
184 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of adding KarXT to existing treatments for mania in adults with Bipolar-I Disorder. This trial focuses on participants experiencing an acute manic episode, with or without mixed features, who are already taking lithium, valproate, or lamotrigine. The study aims to improve mania symptoms, measured by changes in the Young Mania Rating Scale after five weeks. Participants will be randomly assigned to receive either KarXT in addition to their mood stabilizer or a placebo plus their mood stabilizer. The treatments are given in specified doses over the study period, with careful monitoring of side effects and other health measures. The study includes a double-blind design, meaning neither participants nor researchers know which treatment is given to ensure unbiased results. During the trial, participants will undergo regular assessments including psychiatric evaluations, rating scales for mania and other symptoms, and safety monitoring up to seven weeks. Researchers will track symptom changes, treatment responses, and any adverse events. Participants are involved in scheduled visits for evaluations and to maintain stable mood stabilizer doses. The total participation lasts until the primary outcome is measured at week five, with additional safety follow-up up to week seven.

Age: 18Years - 65YearsAll GendersPhase 3
109 locations

1-10 of 13

1